Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tandem Diabetes Care (TNDM) Cash from Financing Activities (2016 - 2025)

Tandem Diabetes Care (TNDM) has disclosed Cash from Financing Activities for 13 consecutive years, with $2.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Financing Activities rose 13.12% year-over-year to $2.6 million, compared with a TTM value of -$43.4 million through Dec 2025, down 618.31%, and an annual FY2025 reading of -$43.4 million, down 618.31% over the prior year.
  • Cash from Financing Activities was $2.6 million for Q4 2025 at Tandem Diabetes Care, up from -$1.6 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $18.8 million in Q3 2021 and bottomed at -$39.7 million in Q2 2025.
  • Average Cash from Financing Activities over 5 years is $1.9 million, with a median of $2.6 million recorded in 2023.
  • The sharpest move saw Cash from Financing Activities soared 2611.28% in 2024, then tumbled 1222.88% in 2025.
  • Year by year, Cash from Financing Activities stood at $15.9 million in 2021, then tumbled by 61.6% to $6.1 million in 2022, then plummeted by 57.1% to $2.6 million in 2023, then fell by 12.04% to $2.3 million in 2024, then increased by 13.12% to $2.6 million in 2025.
  • Business Quant data shows Cash from Financing Activities for TNDM at $2.6 million in Q4 2025, -$1.6 million in Q3 2025, and -$39.7 million in Q2 2025.